Company ProfilePremium

Aligned Genetics, Inc.

Company Profile Analysis

Ticker: 238120.KQ주식회사 얼라인드제네틱스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aligned Genetics, Inc. - Company showcase

Year Founded & Workforce

2008

67 Employees

Aligned Genetics, Inc. logo

Aligned Genetics, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aligned Genetics, Inc. Overview

Aligned Genetics is a small, export-oriented Korean life-science instrumentation company that grew out of Logos Biosystems, a 2008 start-up best known for its LUNA™ family of automated cell counters. It sells under two brands. Logos Biosystems (tagline "Better Tools for Better Science") covers research tools: image-based automated cell counters, bacterial counters, digital and high-content cell imaging systems, and X-CLARITY™ tissue-clearing systems licensed from Stanford's CLARITY technology. Genescale ("Faster Answers for Faster Care") is its molecular-diagnostics brand, aimed at rapid diagnosis at the point of care. The company earns roughly half its revenue from instruments and half from proprietary consumables, which gives it a razor-and-blade recurring stream. Exports account for the large majority of sales; it has US, French and Japanese affiliates and OEM/ODM relationships, including a historical ODM supply arrangement with Olympus and a 2025 OEM contract in China. It is profitable, but growth has slowed sharply since 2023.


What the company does

Aligned Genetics designs, manufactures and sells laboratory instruments and associated consumables for life-science research and bioprocessing, and is building a molecular-diagnostics (MDx) business for clinical use. Its core competence is compact, image-based optical analysis: brightfield and fluorescence imaging, autofocus, and image-analysis software. It applies this to counting and characterising cells (mammalian cells, stem cells, yeast and bacteria), imaging cells in culture, and clearing and imaging whole tissue samples.

The company's own description

The company describes itself on its website as developing innovative technologies and products to open the future of life sciences and molecular diagnostics. It says it is growing two core brands, one for life-science solutions and one for molecular-diagnostic solutions (company website, "Our Brands"). S&P Global's profile, via Simply Wall St, describes the company as offering cellular imaging and biomolecular analysis solutions worldwide, with molecular diagnostics under the Genescale name and imaging and analysis solutions under the Logos Biosystems name.

Independent characterisation

In practice, Aligned Genetics today is overwhelmingly a cell-counter company. The LUNA franchise (LUNA, LUNA-FL, LUNA-II, LUNA-STEM, LUNA-II YF, LUNA-FX7, LUNA-III, LUNA-BX7) and its proprietary counting slides and reagents appear to make up most revenue. That is an inference from the product catalogue, the 50/49 instrument/consumable split, the awards record and the 2025 China OEM deal, all of which centre on cell counters. The company does not publish revenue by product family.

The adjacent businesses are smaller:

Imaging: CELENA® S digital imaging and CELENA® X high-content imaging.

Tissue clearing: X-CLARITY™, a niche neuroscience tool.

Microbial counting: QUANTOM™ / QUANTOM Tx™, notably for microbiome drug manufacturing under GMP.

Emerging projects: SpectraSlide® (2025) and CosmoSort™ cell sorting (a 2024 manufacturing-supply agreement with Meteo Biotech).

The Genescale MDx business has a GMP manufacturing facility (Hanam, 2023) and a Korean MFDS medical-device certification for a molecular-diagnostic instrument (reported September 2026). However, it has not yet produced disclosed, material revenue.

Business and revenue model

DimensionCharacterisationEvidence
Product vs. service mixInstruments about 50%, consumables about 49%, other about 1% (Q2 2026 revenue basis)Butler (DART-derived segment data)
Subscription / licensingNo subscription model disclosed. Historically earned technology fees from ODM contracts (2014 and 2015 ODM agreements with a "global top-tier optical systems company" included technology fees).Company history
ChannelOwn brand sold through about 50 distributors in 41 countries (2016) plus direct subsidiaries in the US (2012), France (2016) and Japan (2025); ODM/OEM supply to global and Chinese partnersSidae (2016); company history
Value-chain positionOriginal equipment manufacturer and brand owner; designs optics, hardware, software and consumables in-house; ODM/OEM supplier to larger instrument brandsCompany history; Sidae (2016)
Customer typesAcademic and government research labs, biopharma R&D, cell and gene therapy and bioprocess developers, microbiome therapeutics manufacturers (QUANTOM Tx under GMP), OEM partners; prospectively hospitals and point-of-care clinical sites (Genescale)Company history; brand pages
End-marketsLife-science research tools (cell counting and analysis, cell imaging, neuroscience tissue clearing), bioprocessing QC, in-vitro diagnostics (molecular)Company website
Geographic orientationExport-heavy: 97.9% export share in H1 2016 (Sidae); about 86% export in trailing-twelve-month data to Q3 2025 (ValueLine Korea)See Section 7

Strategy

Stated strategic themes

The company's public positioning rests on two pillars:

"Better Tools for Better Science": Logos Biosystems life-science solutions.

"Faster Answers for Faster Care": Genescale molecular diagnostics, aiming to provide faster and more accurate diagnosis at the medical front line.

The IR page states that the company is sustaining domestic and international growth on the basis of its competitiveness. A formal medium-term plan, investor-day materials or numerical guidance are not publicly disclosed in accessible sources.

Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescription / intent
LUNA-III™ launch and awards2024 launch; SelectScience 2025 awardRefresh of the core counter franchise
LUNA-BX7™ launch2,025Top-end counter for bioprocess and cell-therapy customers
SpectraSlide® AP-1 launch2,025Portfolio extension
China OEM contract (Shanghai Tech)2,025Access to the Chinese market via a local OEM brand; full-scale deliveries under way per company news
Japan subsidiary2,025Direct presence in Japan
QUANTOM Tx™ GMP adoption2,024Position in microbiome therapeutics manufacturing QC
CosmoSort™ manufacturing supply (Meteo Biotech)2,024Contract manufacturing; entry into cell sorting
National R&D projects2,024Dogma sequencing, single-cell isolation, laser cell sorter (13 national R&D projects in total, per The VC)
Genescale MDx certificationSep 2026First MFDS medical-device certification for the MDx instrument; precondition for clinical sales in Korea
Headquarters relocation2,026Facility consolidation (rationale not disclosed)
Share cancellation and treasury share disposalMay–Sep 2026Capital management (purpose of the disposal not disclosed)
Attendance at 10x Genomics user group annual eventRecent (company news headline)Engagement with the single-cell genomics ecosystem, consistent with "Genetics" positioning

ESG and cost programmes

None disclosed.

Financial targets and guidance

None publicly disclosed. The last known numerical forecast was at the 2016 IPO: break-even in 2016 and KRW 1.9 bn operating profit in 2017 (Sidae). Subsequent results (KRW 2.2–3.3 bn operating income in FY2021–FY2025) indicate that the company did reach sustained profitability.

Products & Services

Launch years are from the company history. Detailed specifications and list prices are not publicly disclosed in accessible sources; capability descriptions reflect company and press characterisations only.

Logos Biosystems — Automated cell counters (LUNA™ family)

ProductLaunchDescription / capabilityTarget customer
LUNA™2,012First-generation image-based automated cell counterResearch labs (cell culture)
LUNA-FL™2,013Dual-fluorescence automated cell counter (viability via fluorescent staining)Labs needing fluorescence-based viability, e.g. primary cells
LUNA-II™2,014Autofocusing brightfield automated cell counterGeneral cell-culture labs
LUNA-STEM™2,014Counter positioned for stem-cell applicationsStem-cell and regenerative-medicine labs
LUNA-II YF™2,016Yeast counterFermentation, brewing and yeast research
LUNA-FX7™2,020Advanced automated cell counter; SelectScience "Best New Life Sciences Product 2020"Bioprocessing, cell and gene therapy
LUNA-III™2,024Latest brightfield counter; SelectScience Best New Life Sciences Product 2025General research and bioprocess labs
LUNA-BX7™2,025Newest high-end counter (specifications not disclosed)Bioprocess and advanced cell-therapy users (inferred from the FX7 lineage)
ODM/OEM counters2015 onwardCounters built for partner brands, e.g. Olympus R1 (2015); Shanghai Tech OEM contract (2025)Partner brands' customers
Counting slides and reagentsOngoingProprietary disposable counting slides/chips (European patent for the counting microchip, 2017) and stainsInstalled base (recurring revenue)

Logos Biosystems — Microbial counting

ProductLaunchDescriptionTarget customer
QUANTOM™2,016Automated bacterial/microbial cell counterMicrobiology and probiotics labs
QUANTOM Tx™About 2023–24 (designated Innovative Product in 2024)Automated bacterial cell counter; adopted under GMP by a European microbiome drug developerLive biotherapeutics and microbiome manufacturers; probiotic QC

Logos Biosystems — Cell imaging

ProductLaunchDescriptionTarget customer
CELENA® S2,015Digital cell imaging system (brightfield/fluorescence benchtop imager)Cell-biology labs
CELENA® X2,018High-content imaging systemDrug discovery, cell-based assays
SpectraSlide® AP-12,025New slide-based product (specifications not disclosed)Research labs
CTC enumeration systemJoint development agreed 2017 with ClinomicsAutomated circulating tumour cell enumeration imaging system; commercial status not disclosedOncology research / clinical

Logos Biosystems — Tissue clearing (neuroscience)

ProductLaunchDescriptionTarget customer
X-CLARITY™ Tissue Clearing System2,015Automated electrophoretic tissue clearing based on Stanford's CLARITY technologyNeuroscience and 3D tissue imaging labs
X-CLARITY™ Polymerization System2,016Hydrogel polymerisation instrument for the CLARITY workflowSame
X-CLARITY™ Tissue Clearing System II2,018Second-generation clearing systemSame
DeepLabel™ Antibody Staining Kit2,019Reagent for antibody penetration into cleared tissue (built on KBRI technology transfer, 2018)Same
Clearing reagentsOngoingFour reagent types were on sale in 2016 (Sidae)Same

Cell sorting

ProductYearDescription
CosmoSort™2024 manufacturing-supply agreement with Meteo BiotechCell sorter manufactured and supplied under contract. National R&D projects in 2024 covered a laser cell sorter and single-cell isolation (The VC). Commercial details not disclosed.

Genescale — Molecular diagnostics

ProductYearDescription
Genescale molecular-diagnostic instrumentMFDS medical-device certification, September 2026Rapid molecular-diagnostic platform ("Faster Answers for Faster Care"), manufactured at the Hanam GMP facility. Model name, assay menu and specifications are not publicly disclosed.
COVID-19 saliva self-antigen test2021 (Russian MoH registration)Antigen (not molecular) self-test registered in Russia; current status not disclosed

Pricing model

Instruments are sold outright, and consumables (slides, reagents) generate recurring pull-through revenue. List prices are not publicly disclosed.

Financial Narrative

Income statement

Source: Butler (DART-derived), annual results in units of KRW 100 m, converted. Growth rates and margins are calculated from these rounded figures. Butler reports FY2025 revenue growth as +1.5% and operating income as −12.1% on unrounded data.

Revenue CAGR, FY2021–FY2025: (16.0 / 11.8)^(1/4) − 1 ≈ 7.9% (calculated).

Gross profit, EBITDA, pre-tax income, EPS and dividends per share are not available as a five-year series from accessible sources:

Quarterly / trailing revenue trajectory: notes and sources

Source: ValueLine Korea: TTM revenue peaked at Q3 2025 and has since declined, which implies Q4 2025 and Q1 2026 were each weaker than the same quarters a year earlier. H1 2026 results (half-year report filed 14 Aug 2026) could not be retrieved in detail.

Balance sheet

A full balance sheet series is not available from accessible sources. Indicative data:

Simply Wall St's summary assessment is an "excellent balance sheet with proven track record". This is a qualitative aggregator rating, not filing data.

Cash flow

Operating cash flow, capex, free cash flow, dividends paid and buybacks are not publicly disclosed in accessible sources. Known capital-allocation events:

  • 2018: equity investment in Biogentec (31.8%; amount not disclosed).

  • 2021–2023: capex on the Hanam production site and MDx GMP facility (amount not disclosed).

  • 2026: headquarters relocation (cost not disclosed).

  • May–September 2026: share cancellation and treasury share disposal (amounts not disclosed).

  • No dividends paid.

Commentary on trends, inflections and drivers

Revenue. Revenue rose from KRW 11.8 bn (FY2021) to KRW 16.0 bn (FY2025), a 7.9% CAGR, but the growth profile has decayed steadily: +16.9% (FY2022), +10.1% (FY2023), +3.9% (FY2024), about +1.3–1.5% (FY2025). TTM revenue then fell to KRW 15.7 bn by Q1 2026. For context, the company had only KRW 4.1 bn of revenue in 2015 (Sidae), so the business roughly quadrupled between 2015 and 2025 before plateauing. The plateau coincides with the well-documented post-pandemic downturn in biopharma and academic tools spending (2023–2025), which hit cell-culture instrument demand industry-wide. It also coincides with intensifying price competition in entry-level cell counters. The 2025 China OEM contract and the LUNA-III / LUNA-BX7 launches are the visible levers for re-acceleration, but their effect is not evident in data through Q1 2026.

Profitability. Operating margin peaked at 21.7% in FY2023 and compressed to 15.0% in FY2025, with operating income down from KRW 3.3 bn to KRW 2.4 bn. With revenue roughly flat, the compression points to rising operating costs: R&D for MDx and new LUNA models, overseas subsidiary build-out (Japan, 2025), and GMP facility overheads. The TTM gross margin of about 69% (to Sep 2025) is high for an instrument maker. That reflects the consumables-rich mix and in-house optics and software.

Net income volatility. Net income has repeatedly diverged from operating income: KRW 5.5 bn in FY2021 versus KRW 2.2 bn operating income, and KRW 4.1 bn in FY2024 versus KRW 2.8 bn. This indicates material non-operating items. Plausible items include financial income on cash balances, valuation changes on financial assets, equity-method results from Biogentec, FX gains on USD/EUR receivables given the export mix, and tax effects. The specific items are not disclosed in accessible sources, so net income should not be extrapolated as a run-rate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Brand Details

BrandScopeMain products

Logos Biosystems

Life-science research tools

LUNA™ cell counters, QUANTOM™ bacterial counters, CELENA® imaging systems, X-CLARITY™ tissue clearing, DeepLabel™ reagents, counting slides and consumables, SpectraSlide®

Genescale

Molecular diagnostics (point of care / rapid)

Molecular-diagnostic instrument (MFDS-certified September 2026) and related assays; product names and specifications not publicly disclosed

Product Type Details

Product typeShare of revenue, Q2 2026 (%)

Instruments (장비)

50

Consumables (소모품)

49

Other

1

Revenue by Segment

MetricTTM Mar-2025TTM Jun-2025TTM Sep-2025

Total revenue (KRW Bn)

16.5017.1717.35

Domestic revenue (KRW Bn)

2.082.182.35

Export revenue (KRW Bn)

14.4214.9814.99

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityCountryFunctionYearOwnership

Aligned Genetics, Inc.

Korea

Parent; R&D, manufacturing, headquarters

2008

Listed

Logos Biosystems, Inc.

USA

Sales and service subsidiary

2012

Not publicly disclosed (described as a subsidiary)

Logos Biosystems SARL

France

European sales subsidiary

2016

Not publicly disclosed (described as a subsidiary)

Japan branch/subsidiary

Japan

Sales

2025—

Biogentec (바이오젠텍)

Korea

IVD developer (blood and molecular diagnostics); Korea University Hospital spin-off

Investment in 2018

31.8% at the time of investment (2018); current stake not publicly disclosed

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

11.813.815.215.816.0

Operating income (KRW Bn)

2.22.83.32.82.4

Net income (KRW Bn)

5.52.33.24.12.9

Revenue growth YoY (%)

—16.910.13.91.3

Operating margin (%)

18.620.321.717.715.0

Net margin (%)

46.616.721.125.918.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

MetricStatus

Gross profit (annual)

Not publicly disclosed in accessible sources. TTM to 30 Sep 2025: revenue KRW 17.4 bn, cost of revenue KRW 5.4 bn, gross profit KRW 12.0 bn, gross margin 69.0% (Simply Wall St / S&P)

EPS (basic/diluted)

Not publicly disclosed as an annual series. TTM EPS: KRW 197 (Investing.com, Aug 2026); KRW 329 (Investing.com, Sep 2026). The figures differ by period.

Dividends per share

Nil (dividend yield 0.00%, StockHub; none disclosed by Butler)

Income Statement

MetricTTM Mar-2025TTM Jun-2025TTM Sep-2025TTM Dec-2025TTM Mar-2026

Revenue TTM (KRW Bn)

16.5017.1717.3516.0115.73

Financial Analysis — Total assets

ItemValueSource / note

Total assets

Not publicly disclosed (accessible sources)

—

Cash & equivalents

Not publicly disclosed (accessible sources)

Historically strong liquidity: in 2018, Hankyung's quant screen ranked the company in the top 0.21% of the market on quick ratio

Total debt

Not publicly disclosed. A Simply Wall St headline describes debt as being used "safely"; The VC records one convertible bond issue (amount and date not disclosed)

Simply Wall St; The VC

Book equity (implied)

About KRW 39.2 bn (Butler: KRW 35.3 bn market cap ÷ 0.90 P/B) or about KRW 33.1 bn (StockHub: KRW 35.8 bn ÷ 1.08 P/B)

Implied from aggregator multiples, not from filings; the two sources differ

Treasury shares

0.32% of share count (October 2026)

Butler

Financial Analysis — ROE

RatioValueSource / note

ROE

11.8% (Butler, Oct 2026); 7.39% (ValueLine, Jun 2026); 6.42% (StockHub, Oct 2026)

Sources differ by period and method

ROA

6.8% (Simply Wall St summary metric)

Aggregator; period TTM to Sep 2025

Current ratio

Not publicly disclosed; liquidity historically very high (2018 quick-ratio ranking)

—

Debt/equity

Not publicly disclosed; aggregator describes debt as well covered

—

Net debt/EBITDA

Not publicly disclosed (likely net cash)

—

P/E (TTM)

7.60 (Butler); 9.24 (StockHub); 15.67 (ValueLine, Jun 2026); 16.97 (StockHub EN, earlier date)

Varies with price date and TTM period

P/B

0.90 (Butler); 1.08 (StockHub); 1.16 (ValueLine, Jun 2026)

—

Revenue by Region and Revenue by Region (%)

RegionTTM Mar-2025TTM Jun-2025TTM Sep-2025

Domestic Korea (KRW Bn)

2.082.182.35

Export (KRW Bn)

14.4214.9814.99

Export share (%)

87.487.386.4

Export Share by Period

PeriodExport share (%)Source

H1 2016

97.9

Sidae (IPO coverage)

TTM Sep-2025

86.4

ValueLine Korea (calculated)

Revenue by Region

Metric2014201620202022

Export Tower threshold achieved (USD Mn)

1357

Share Price and Market Valuation

Metric2018-07-022026-03-202026-06-252026-08-052026-09-272026-10-13

Share price (KRW)

14,950—3,0752,9002,9652,520

Market cap (KRW Bn)

48.765.243.541.242.235.8

Share Price & Returns

PeriodReturnSource

1-year to 27 Sep 2026

−11.2%

Investing.com

1-year to 5 Aug 2026

−16.5%

Investing.com

3-year

A Simply Wall St article headline reports a 29% gain over three years; its date is not shown, so this is not current

Simply Wall St

5-year

Not publicly disclosed in accessible sources

—

52-week range

KRW 2,380 – 6,050

Investing.com; StockHub

Price position

About 4% of the 52-week range (13 Oct 2026)

StockHub

Valuation Multiples

MultipleAligned GeneticsSource

P/E (TTM)

7.60 (Butler) / 9.24 (StockHub)

Oct 2026

P/B

0.90 (Butler) / 1.08 (StockHub)

Oct 2026

EV/Sales

Not computable (net cash/debt not disclosed); price/sales about 2.2x (KRW 35.3 bn market cap ÷ KRW 15.73 bn TTM revenue, calculated)

Calculated

Capital Markets

ItemDetail

Dividend history

No dividends; yield 0.00%

Treasury share disposal

Decision in June 2026 (amended 30 Jun); completed per the 3 Sep 2026 report.

Treasury shares held

0.32% (Oct 2026)

Analyst Conclusions

Management guidance and consensus

There is no public guidance and no consensus estimates.

Bull case

  1. The China OEM and MDx launch restart growth. The 2025 Shanghai Tech OEM contract with full-scale deliveries, plus the September 2026 MFDS certification of the Genescale instrument manufactured in the 2023 Hanam GMP facility, are two concrete new revenue channels on a small KRW 16 bn base. Modest wins would move the growth rate visibly.

  2. A quality franchise at a deep value multiple. The company has five consecutive years of operating profit, about 69% gross margin and 49% consumables revenue, yet trades at about 0.9–1.1x book and 7.6–9.2x trailing earnings, near its 52-week low.

  3. Premium bioprocess positioning. LUNA-FX7 and BX7, award-winning LUNA-III, and the QUANTOM Tx GMP adoption tie the company to the structurally growing cell and gene therapy and live biotherapeutic QC markets, where validated instruments are sticky.

Bear case

  1. Structural maturity of the core business. Growth has decayed every year since FY2022, to about 1.5%, and TTM revenue was declining into 2026. Cell counters face entrenched giants and low-end price competition.

  2. Margin erosion and non-recurring earnings. Operating margin fell from 21.7% to 15.0% over two years. Reported net income repeatedly depends on non-operating items, so the low P/E may overstate sustainable earnings power.

  3. MDx is a costly late entry. Eight years after the 2018 Biogentec investment, Genescale has only just received domestic certification and faces Seegene, SD Biosensor and other incumbents. Spending could continue to dilute margins without commensurate revenue.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableWhat to watch
Q3 2026 quarterly report (due around mid-November 2026)Whether TTM revenue stabilises above KRW 15.7 bn; operating margin trajectory
FY2026 annual report (around March 2027)Full-year growth, R&D spend, subsidiary results, customer concentration, Biogentec carrying value
China OEM volumesDisclosure of order sizes or a China revenue line
Genescale commercialisationFirst hospital or clinic placements, assay approvals, reimbursement status, CE-IVDR filings
Capital allocationFurther share cancellations or buybacks; any dividend initiation; use of treasury share disposal proceeds
Insider transactionsFollow-up filings after the June 2026 ownership report
Product cycleLUNA-BX7 adoption; any FDA/GMP-oriented software validation packages
FXKRW/USD and KRW/EUR moves affecting reported revenue and non-operating income

Analyst verdict

Aligned Genetics is a niche life-science instrument maker with real but small competitive strengths, now at a strategic inflection. Its core LUNA cell-counter franchise is genuinely well regarded. The evidence is a string of SelectScience awards culminating in the 2025 Best New Product award for LUNA-III, a historical ODM relationship with Olympus, and a fresh OEM deal in China. The economics are attractive: roughly 69% gross margins and half of revenue from consumables. The company has also been profitable at the operating level every year from FY2021 to FY2025.

The financial trajectory, however, has turned. Revenue growth fell from about 17% in FY2022 to about 1.5% in FY2025, and trailing revenue declined into 2026. Operating margin compressed by almost seven percentage points in two years. Net income has been flattered by non-operating gains in several years, so headline P/E ratios of 7.6–9.2x likely understate the true multiple on recurring earnings. The market has noticed: the share price fell by more than half from its 52-week high and now sits near the bottom of its range, at roughly book value.

The investment question therefore turns on whether the two new legs, China OEM volume and Genescale molecular diagnostics, can offset maturity in the core business. The September 2026 MFDS certification is a necessary, but far from sufficient, step into a fiercely contested Korean MDx market. With no guidance, no analyst coverage, thin liquidity and limited English-language disclosure, visibility is poor.

On balance, Aligned Genetics screens as a low-expectation, asset-backed micro-cap with optionality rather than a demonstrated growth story. The next two quarterly prints (Q3 2026 and FY2026) are decisive. Stabilisation of trailing revenue above about KRW 16 bn, together with evidence of China and MDx revenue, would support a re-rating. A further decline would confirm a value trap. Investors should obtain the DART annual and half-year reports to verify balance-sheet strength, cash flow and ownership before drawing firm conclusions.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleBackgroundCompensation

Jung Yeon-cheol (정연철)

CEO and representative director

Led the IPO and the 2018 Biogentec diagnostics investment; prior roles and education not publicly disclosed in accessible sources

Not publicly disclosed. Korean rules require individual pay disclosure only above KRW 500 m.

Other C-suite (CFO, CTO, etc.)

—

Not publicly disclosed in accessible sources

—

“—” = not publicly disclosed.

Major Shareholders

HolderStakeSource

Largest shareholder (presumed CEO and related parties)

Not publicly disclosed in accessible sources

—

Historical VC investors

KDR (2012), Partners Investment (2014), Suprema Investment (2016); current holdings not disclosed

Company history

Institutional top-10

Not publicly disclosed; institutional ownership of KOSDAQ micro-caps is typically minimal

—

Treasury shares

0.32%

Butler

Competitive Landscape

Competitors by Segment

Product areaCompetitorCompeting products (illustrative)Relative positioning of Aligned Genetics

Automated cell counters

Thermo Fisher Scientific (USA)

Countess™ series

Thermo dominates on brand and channel; Logos competes on image quality, fluorescence and price, with strong SelectScience reviews

Automated cell counters

Bio-Rad Laboratories (USA)

TC20™

Mid-market rival

Automated cell counters / bioprocess

Beckman Coulter (Danaher, USA)

Vi-CELL™ BLU

Incumbent in GMP bioprocess; LUNA-FX7/BX7 target the same users

Automated cell counters

Revvity (Nexcelom, USA)

Cellometer®

Direct image-based rival in fluorescence counting

Automated cell counters

ChemoMetec (Denmark)

NucleoCounter®

Strong in cell and gene therapy QC

Automated cell counters

DeNovix (USA), Corning (USA), Olympus/Evident (Japan)

CellDrop™; Corning counter; Evident R1 (originally a Logos ODM product)

Low-to-mid tier; the Evident relationship is both partner and competitor

Cell imaging / high-content

Molecular Devices (Danaher), Revvity, Agilent (BioTek), Sartorius, Thermo Fisher

ImageXpress®; Operetta®/Opera®; Cytation™; Incucyte®; CellInsight™

CELENA is a small player against large incumbents

Tissue clearing

LifeCanvas Technologies (USA), Miltenyi Biotec (Germany)

SmartBatch+; clearing workflows

X-CLARITY was first to market; niche competition

Molecular diagnostics (point of care / rapid)

Cepheid (Danaher), Seegene, SD Biosensor, Bioneer, Gene System (진시스템)

GeneXpert®; Seegene platforms; Gene System's rapid PCR (UF-340)

Genescale is pre-revenue against entrenched local and global platforms

Peer Comparison FY2024

MetricAligned GeneticsThermo FisherDanaherBio-Rad

Revenue, FY2024

KRW 15.8 bn (about USD 0.012 bn)

About USD 42.9 bn

About USD 23.9 bn

About USD 2.6 bn

Revenue growth, FY2024

+3.9%

Roughly flat

Roughly flat to down

Roughly down low single digits

Operating margin, FY2024

17.7%

Not compiled

Not compiled

Not compiled

R&D intensity

—

Not compiled

Not compiled

Not compiled

“—” = not publicly disclosed.

Company Snapshot

$11.3M

Revenue

67

Employees

2008

Founded

Gunpo, South Korea

Headquarters

SWOT Analysis

Strengths

  • Consistently profitable: Operating income positive in every year FY2021–FY2025 (KRW 2.2–3.3 bn); operating margin 15.0–21.7% (Butler)
  • High gross margin: About 69.0% TTM to Sep 2025 (KRW 12.0 bn gross profit on KRW 17.4 bn revenue; Simply Wall St)
  • Recurring revenue base: Consumables were 49% of revenue in Q2 2026 (Butler)
  • Global commercial reach: About 86% export share (TTM Sep 2025); subsidiaries in the US, France and Japan; USD 7 m Export Tower (2022)
  • Product excellence recognised by users: SelectScience Diamond Seal (2022), Company of the Year (2023), Best New Product (2020, 2025)
  • OEM/ODM validation: Olympus ODM (2014–2015; Olympus R1); Shanghai Tech OEM (2025); Meteo Biotech manufacturing contract (2024)
  • Regulated-market foothold: QUANTOM Tx adopted under GMP for a European microbiome drug (2024); MDx GMP facility (2023); MFDS certification (2026)

Weaknesses

  • Growth has stalled: Revenue growth slowed from 16.9% (FY2022) to about 1.5% (FY2025); TTM revenue fell from KRW 17.35 bn (Sep 2025) to 15.73 bn (Mar 2026)
  • Margin compression: Operating margin fell from 21.7% (FY2023) to 15.0% (FY2025); FY2025 operating income −12.1%
  • Sub-scale: FY2025 revenue KRW 16.0 bn; 62–67 employees
  • Volatile, low-quality earnings composition: FY2021 net income (KRW 5.5 bn) was 2.5 times operating income; FY2024 net income KRW 4.1 bn vs. operating income KRW 2.8 bn
  • Product concentration: Catalogue and awards centred on LUNA counters; no disclosed product-level revenue diversification
  • Limited disclosure and visibility: No analyst coverage (StockHub: zero reports); no English annual report; no guidance

Opportunities

  • China volume via OEM: 2025 Shanghai Tech OEM contract; company news on full-scale deliveries
  • Clinical MDx sales in Korea: MFDS medical-device certification (Sep 2026) plus the Hanam GMP facility (2023)
  • Bioprocess and cell-therapy QC upgrade cycle: LUNA-BX7 (2025) and LUNA-FX7 positioned at high-value GMP users
  • Live biotherapeutics QC standard: QUANTOM Tx GMP reference customer (2024)
  • Japan direct sales: Japanese subsidiary established in 2025; historic Olympus ties
  • Single-cell and cell-sorting adjacency: CosmoSort (2024); national R&D projects on laser cell sorting and single-cell isolation; 10x Genomics user-community engagement

Threats

  • Large-cap competitors with bundling power: Thermo Fisher (Countess), Danaher/Beckman (Vi-CELL), Revvity (Cellometer), each in a multi-billion-dollar company
  • Crowded Korean MDx market: Seegene, SD Biosensor, Bioneer and Gene System already established
  • Research-funding cyclicality: Growth deceleration across FY2023–FY2025 coincides with an industry-wide tools downturn
  • FX volatility: Export share of about 86–98%
  • OEM partner substitution: ODM/OEM partners (Olympus/Evident; Shanghai Tech) could develop in-house products or switch suppliers
  • Equity-market de-rating: Share price fell from a 52-week high of KRW 6,050 to about KRW 2,480–2,520 (Oct 2026); market cap down from KRW 65.2 bn (Mar 2026) to about KRW 35 bn

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (exact date not disclosed)LUNA-BX7™ launchedTop-end counter refresh
2025SpectraSlide® AP-1 launchedPortfolio extension
2025LUNA-III™ named SelectScience Best New Life Sciences Product of 2025Third-party validation of the core franchise
2025OEM contract for automated cell counters with Shanghai Tech (China)New channel into China
2025Company news: full-scale delivery of automated cell counters into ChinaPotential growth driver
2025Japanese branch/subsidiary establishedDirect presence in Japan
30 Sep 2025 (period end)TTM revenue peaks at KRW 17.35 bn (ValueLine)High-water mark
FY2025 (reported early 2026)Revenue KRW 16.0 bn (+1.5%); operating income KRW 2.4 bn (−12.1%); net income KRW 2.9 bnGrowth stall and margin compression
Q1 2026TTM revenue falls to KRW 15.73 bnContinued softness
20 Mar 2026Market cap KRW 65.2 bn (Simply Wall St snapshot)Near the 52-week high zone (52-week high KRW 6,050)
2026Headquarters relocated to Gunpo-siFacility change
29 May 2026Share cancellation decisionShareholder-return / capital action
25 Jun 2026Share price KRW 3,075; market cap KRW 43.5 bn (ValueLine)—
26 Jun 2026Executive/major shareholder ownership report filed–
30 Jun 2026Amended major-matters report on the treasury share disposal decisionTreasury shares to be sold or transferred
5 Aug 2026Share price KRW 2,900 on unusually high volume (418.7k shares vs. a 3-month average of 33.5k; intraday range KRW 2,600–3,250)Event-driven trading (catalyst not identified)
14 Aug 2026H1 2026 half-year report filed–
3 Sep 2026Treasury share disposal result report filedDisposal completed
Sep 2026Genescale molecular-diagnostic instrument receives Korean MFDS medical-device certification (Newsis)First regulatory milestone for MDx clinical sales in Korea
27 Sep 2026Share price KRW 2,965; market cap KRW 42.2 bn; 1-year change −11.2%—
13 Oct 2026Share price KRW 2,520; market cap KRW 35.8 bn; near the 52-week low (KRW 2,380)Sell-off despite the MDx certification
Undated (recent company news)Participation in the 10x Genomics users group annual eventSingle-cell ecosystem engagement

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Total revenue rose from KRW 16,500 Mn in Mar-2025 to KRW 17,350 Mn in Sep-2025.
Aligned Genetics, Inc. — Revenue by Segment
Series (KRW Mn)Mar-2025Jun-2025Sep-2025
Total revenue16,50017,17017,350
Domestic revenue2,0802,1802,350
Export revenue14,42014,98014,990

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Aligned Genetics corporate website, alignedgenetics.com (home and history pages), accessed Oct 2026 — Brands, taglines, history and milestones (2008–2026), HQ address, news headlines
  2. Butler (butler.works), company page 01073678, accessed Oct 2026 — FY2021–FY2025 revenue, operating income and net income; segment mix (Q2 2026); disclosures list; market cap, P/E, P/B, ROE, treasury share ratio
  3. ValueLine Korea ( data as of 25 Jun 2026 — TTM revenue and domestic/export split; shares outstanding; ROE; P/E; P/B (valueline.co.kr)
  4. StockHub ( accessed 13 Oct 2026 — Share price, market cap, P/E, P/B, ROE, 52-week range, analyst coverage (zero), Newsis MFDS headline, peer commentary (stockhub.kr)
  5. Simply Wall St (S&P Global Market Intelligence data), snapshot 20 Mar 2026 — Founding year, listing date, address, employees, CEO, TTM revenue/gross profit/earnings, name-change date, market cap
  6. Investing.com (multiple language editions), Aug and Sep 2026 — Share price, volume, 52-week range, 1-year change, TTM EPS, split count
  7. The VC ( 2026 — Founding month, CEO, employees (June 2026), patents, national R&D, convertible bond record (thevc.kr)
  8. Sidae (sidae.com), 18 Oct 2016 — IPO terms, 2015 revenue, R&D intensity, export share, Olympus ODM and revenue share, distribution network, CEO statements
  9. BioSpectator ( 2018 — Biogentec 31.8% investment and MDx strategy; CLARITY commercialisation (biospectator.com)
  10. Hankyung (hankyung.com), 2 Jul 2018 — Historical share price, market cap and liquidity ranking

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.